ALX Oncology Has ‘Elevated Valuation’ – Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer
4
0
Thursday, ALX Oncology Holdings (NASDAQ:ALXO) reported a fourth-quarter 2023 EPS loss of $(0.93), missing the consensus of $(0.86).
As of December 31, 2023, cash equivalents and investments were $218.1 million.
The company says the cash balance and the ability to draw down an additional $40 million of its term loan are sufficient to fund planned operations into early 2026.
In October 2023, ALX Oncology released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzumab, Cyramza (ramucirumab), and paclitaxel for HER2-positive gastric/gastroesophageal junction …
Full story available on Benzinga.com
Visited 4 times, 1 visit(s) today
Related posts:
- Home Run To Homewrecker – Analyst Cautious On Homebuilders, Downgrades Key Players
- Aclaris Therapeutics’ ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
- Archer-Daniels-Midland’s Financial Figures ‘Are Too High,’ Analyst Downgrades Stock
- After 130% Surge, AMD Faces Uncertain Road Ahead: Top Analyst Says Chipmaker’s Future Shrouded In Doubt